NIH trial with omega-3
This article was originally published in The Tan Sheet
Executive Summary
The National Institute on Aging announces May 10 it will conduct a clinical trial evaluating whether omega-3 fatty acids slow the progression of cognitive and functional decline in people with Alzheimer's disease. The trial will take place at 51 sites and will include 400 participants, who will take either 2 g daily of Martek Biosciences donated life'sDHA or placebo. The National Institutes of Health agency says the study is one of a number it will undertake in the next few years to test compounds that might help prevent or delay Alzheimer's. A study published in the November Archives of Neurology found a higher level of DHA reduces the risk of developing all-cause dementia (1"The Tan Sheet" Nov. 20, 2006, p. 6)...
You may also be interested in...
Martek’s DHA Pricing Stand Based On Long-Term Growth, Fish Oil Competition
Martek Biosciences has largely avoided raising prices on its nutritional oil products despite rising material costs because the firm does not want to surrender its competitive advantage in the infant formula and other markets, according to CEO Steve Durbin
Higher DHA Intake Associated With Reduced Risk Of Dementia – JAMA Study
A higher level of DHA in the blood is associated with a 47% reduction in the risk of developing all-cause dementia, a study in the November Archives of Neurology finds
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.